Pierre Chancel - Sanofi
Pierre Chancel - Sanofi
Pierre Chancel - Sanofi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
The ORIGIN Study could Potentially further Change the<br />
Landscape of Type 2 Diabetes Treatment<br />
Patients at high CV<br />
risk and IFG, IGT,<br />
newly detected or<br />
established diabetes<br />
(on 0 or 1 oral agent)<br />
R<br />
12,600 patients 40 countries Results in 2012<br />
Other agents for<br />
glycemic control<br />
Endpoints:<br />
CV morbidity/mortality<br />
All cause mortality<br />
Risk of diabetic microvascular<br />
outcomes<br />
Rate of progression of IFG or<br />
IGT to type 2 diabetes<br />
Can early use of Lantus ® reduce CV events in early/pre-diabetic<br />
patients more than standard glycemic care?<br />
8
Change language